Breadcrumb

What's New at the RI-MUHC ?

Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19

Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations

COVID-19 Q&A on dealing with pandemic fatigue

“We need to strike a balance and take our anxiety down from an unhealthy to a manageable level,” says researcher Jason Harley

New study shows that persistence of ADHD into adulthood is an important predictor of car crash risk

RI-MUHC researcher Dr. Lily Hechtman is senior author of a 20-year study

Research suggests greater access to specific HIV and tuberculosis medications is needed worldwide

Postdoctoral fellows at the RI-MUHC carried out primary statistical analyses for study published in The Lancet

Inappropriate prescriptions sending hospitalized seniors back to the ER

Improving hospital prescribing practices may reduce risk of rehospitalization and death

Study identifies strategies to reduce breast cancer growth and related skeletal lesions

RI-MUHC team publishes findings in the journal, Bone Research

Early treatment trial of hydroxychloroquine shows no symptomatic benefit for COVID-19 patients

Adult outpatients with mild symptoms of COVID-19 don’t benefit from taking hydroxychloroquine

Sodium found to regulate the biological clock of mice

New study by RI-MUHC researchers first to establish that physiological signals influence circadian rhythms

At the heart of precision medicine

New translational collaboration aims to transform approach to heart muscle disease

Learn more about the RI-MUHC